Beam Therapeutics Inc. Other Noncash Income (Expense)
Beam Therapeutics Inc. (BEAM) reported Other Noncash Income (Expense) of -$3.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2025-02-25
- Beam Therapeutics Inc. other noncash income (expense) for the quarter ending 2022-12-31 was $0.00.
- Beam Therapeutics Inc. other noncash income (expense) for the quarter ending 2022-09-30 was $0.00.
- Beam Therapeutics Inc. other noncash income (expense) for the quarter ending 2022-06-30 was $0.00.
- Beam Therapeutics Inc. other noncash income (expense) for the quarter ending 2022-03-31 was -$3.00K.
- Beam Therapeutics Inc. other noncash income (expense) for fiscal 2022 was -$3.00K.
- Beam Therapeutics Inc. other noncash income (expense) for fiscal 2021 was -$63.00K, a 112.19% decline from fiscal 2020.
- Beam Therapeutics Inc. other noncash income (expense) for fiscal 2020 was $517.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | -$3.00K 10-K · filed 2025-02-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | -$3.00K 10-Q · filed 2023-11-08 | -$3.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.00K 10-Q · filed 2023-08-08 | -$3.00K derived: sum of 3 quarters · filed 2024-02-27 | -$3.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$3.00K 10-Q · filed 2023-05-10 | -$3.00K derived: sum of 2 quarters · filed 2024-02-27 | -$3.00K derived: sum of 3 quarters · filed 2024-02-27 | -$3.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | -$63.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | -$63.00K 10-Q · filed 2022-11-07 | -$63.00K derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$63.00K 10-Q · filed 2022-08-09 | -$63.00K derived: sum of 3 quarters · filed 2022-08-09 | -$63.00K derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$63.00K 10-Q · filed 2022-05-09 | $976.00K 10-Q · filed 2021-05-11 | -$63.00K derived: sum of 2 quarters · filed 2022-05-09 | -$63.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $517.00K 10-K · filed 2021-03-15 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $517.00K 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $517.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |